AACR 2023 | Arginine deprivation therapy in mesothelioma

Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, provides an overview of arginine deprivation therapy. Whilst there has been previous research elucidating the link between arginine deprivation and tumor control, successful trials such as the Phase II/III study (NCT02709512) of pegargiminase in non-epithelioid pleural mesothelioma have only recently been able to take place. Reduced levels of arginine inhibit nucleotide synthesis, resulting in tumor shrinkage. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.